Navigation Links
ThromboGenics NV - Q3 2009 Business Update
Date:11/4/2009

LEUVEN, Belgium, November 4 /PRNewswire-FirstCall/ -- ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on innovative medicines for eye disease, vascular disease and cancer, is today issuing a business update for the period ending 30 September, 2009.

Patrik De Haes, CEO of ThromboGenics, said:

"ThromboGenics' clinical development programs have continued to make significant progress. We are very happy to have completed patient enrolment for the US Phase III study with microplasmin and recruitment in our second Phase III trial is continuing to make excellent progress. Microplasmin is central to our aim of building a successful integrated company focused on cutting edge ophthalmic medicines, that is positioned to deliver significant shareholder value.

We have also recently completed patient recruitment of a Phase II study with TB-402, assessing it as a DVT prophylactic in patients undergoing knee replacement, ahead of schedule. Our experience with TB-402 suggests that this long acting product has the potential to be an important new entrant into the anticoagulant market making it an attractive out-licensing opportunity. Our partnership with Roche for the novel anti-cancer antibody TB-403 continues to make good progress, with results from the Phase Ib trial to be presented later this month at the American Association for Cancer Research conference."

    Financial Update

    - ThromboGenics achieved revenues of EUR3.7 million in the
      third quarter of 2009, the majority of which came from out-licensing.
      R&D expenses were EUR12.6 million during this nine month period. In
      Addition EUR10.4 million of expenses related to the microplasmin Phase
      III clinical program have been capitalized over the first nine months
      of this year.
    - As of September 30, 2009, ThromboGenics had EUR43.1 million
      in cash and cash equivalents. This compares to 
'/>"/>
SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
2. ThromboGenics is Shortlisted for "Biotech Company of the Year" and "Licensing Deal of the Year" at Scrip Awards 2009
3. ThromboGenics NV Announces Business Update and Half Year Results 2009
4. ThromboGenics NV: Business Update
5. ThromboGenics Announces Business Update and 2008 Full Year Results
6. ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis
7. ThromboGenics N.V.: Business Update
8. ThromboGenics Announces Half Year Results 2008
9. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
10. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
11. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... September 22, 2014 METTLER TOLEDO ... and pallet measuring device CNS110 ScanTape™ . ... data entry, offering greater ease and accuracy for ... result can significantly enhance productivity—an important benefit for ... processing volume equals profits. , Usable at ...
(Date:9/21/2014)... Basel in Switzerland have succeeded in observing the ... the first time. These extremely weak spectra offer ... and may also contribute to the development of ... published in the scientific journal Nature Physics ... between matter and light, is probably the most ...
(Date:9/20/2014)... (PRWEB) September 20, 2014 Entries are ... Prism Awards for Photonics Innovation . The international ... multi-billion dollar optics and photonics industry, and is sponsored ... photonics , and Photonics Media . , The ... versatility of photonics, said SPIE CEO Eugene Arthurs. , ...
(Date:9/19/2014)... BRISBANE, Calif., Sept. 19, 2014  InterMune, Inc. (Nasdaq: ... into a Memorandum of Understanding to settle the litigation ... Agreement and Plan of Merger dated as of August ... and InterMune, Inc.  As one term of the Memorandum ... disclosures set forth in the attached exhibit reflecting the ...
Breaking Biology Technology:ScanTape™ Handheld Dimensioner Increases Processing Volume 2Uncovering the forbidden side of molecules 2Entry deadline is 10 October for international photonics Prism Awards 2Entry deadline is 10 October for international photonics Prism Awards 3Entry deadline is 10 October for international photonics Prism Awards 4InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 2InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 3InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 4InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 5InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 6InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 7InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 8InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 9InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 10InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 11InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 12InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 13InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 14InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 15InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 16InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 17InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 18InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 19
... OREX ), a biopharmaceutical company focused on the treatment of,obesity, ... Annual,BIO CEO & Investor Conference. The details are as follows: , ... Monday, February 9, 2009, Time: 3:45 p.m. ... Room, New York, Speaker: Graham Cooper, Chief Financial ...
... and Investments of $65.0 MillionRICHMOND, Calif., Feb. 4 Sangamo ... quarter and full year 2008 financial results and accomplishments and ... December 31, 2008, Sangamo reported a consolidated net loss of ... loss of $6.7 million, or $0.17 per share, for the ...
... Experts Enhance Presence in U.S. with New Facility and ... CustomersRALEIGH, N.C., Feb. 4 - As part of an ... Datatrial ( www.datatrial.com ) has significantly bolstered its data ... a move to a larger office space, which will ...
Cached Biology Technology:Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results 2Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results 3Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results 4Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results 5Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results 6Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results 7Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results 8Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results 9Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results 10New General Manager, Transition to New Raleigh Offices Highlight Datatrial's Expansion of North American Operations 2
(Date:9/22/2014)... in recent years has been identified as the plant,s ... aroma also summons beneficial insects to the rescue. , ... the environment via the emission of volatile organic compounds, ... wasps to come to the plant that is being ... Dr. Michael Kolomiets, Texas A&M AgriLife Research plant pathologist ...
(Date:9/22/2014)... Manufacturing biofuels from food crop by-products such as straw ... work of scientists in the UK and France. ... Research Council (BBSRC) have discovered variant straw plants whose ... biofuels, but which are not significantly smaller or weaker ... ease pressure on global food security as biofuels from ...
(Date:9/22/2014)... 2011 the Society of Environmental Toxicology and Chemistry (SETAC) ... and prioritize the scientific research needed to understand the ... the environment. The effort was extended, and results ... Society,s international journal, Integrated Environmental Assessment and Management ... a podcast interviewing the lead author of the study, ...
Breaking Biology News(10 mins):Mown grass smell sends SOS for help in resisting insect attacks, researchers say 2Mown grass smell sends SOS for help in resisting insect attacks, researchers say 3Plant variants point the way to improved biofuel production 2Priorities for research on pharmaceutical and personal care products in the environment 2
... release is available in Spanish . ... have improved on an existing method for removing contaminants ... waters additional protection against runoff containing pollutants from point ... urban landscapes. "Filter socks" containing compost ...
... (22 July 2010) -- Howard A. Schmidt, national cybersecurity coordinator ... featured speaker at the 2010 IEEE International Conference on Technologies ... Starnes E. Walker and Christopher Doyle of the U.S. Department ... join Schmidt as featured speakers. HST 10 will ...
... 22, 2010) - A new study published in the ... people who consume low-calorie sweeteners are able to significantly ... In fact, study participants who received the ... and there was no difference in hunger levels despite ...
Cached Biology News:'Super socks' help stem pollution runoff 2New research: Sugar substitutes help reduce caloric intake without overeating or hunger 2
Candida (IgA) -Ab EIA Sample Size: 5 l...
... Oxidized LDL (Competitive) EIA Principle: ... the monoclonal antibody 4E6. Oxidized LDL in the ... LDL bound to the microtiter well for the ... a washing st Sample Size: 25 ...
OptiBuffer is a fully optimised medium, designed for,the electroporation of eukaryotic cells. OptiBuffer,improves both transfection efficiencies and survival,rates over PBS or other standard culture...
... in solution or in a gel piece, we ... will be digested to produce a mixture of ... are determined by MALDI-TOF, and the amino acid ... MALDI-TOF will be determined by MALDI-TOF/TOF. The masses ...
Biology Products: